- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04419584
Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
A Randomized Placebo-Controlled Clinical Trial of an Innovative Herbal Formula for Atopic Dermatitis in Children: Evaluations of Modified Qing-Ying Decoction on Efficacy and Gut Microbiome
The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution.
This is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules. Subjects will have 12-week of treatment, and then a 4-week follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- The Chinese University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 4 to 17 (Chinese only);
- With EASI ≥ 10;
- Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous papules and plaques; and
- Provide written informed consent form (signed by one of their parents)
Exclusion Criteria:
- History of allergy to Chinese medicines;
- AD with Yang deficiency in syndrome differentiation, such as pale looking, always feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as urinary difficulty, excessive urination or incontinence
- Known overt bacterial infections in the skin;
- Known pregnancy;
- Known severe medical conditions, such as cardiovascular, liver or renal dysfunction or Diabetes Mellitus;
- Having used oral corticosteroids, oral antibiotics, other immunosuppressive or any preparation of oral herbal medicines for the treatment of AD in the past month;
- Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitis or psoriasis; and
- Has taken anti-coagulant or anti-platelet drugs in the past month.
- Has taken any probiotics, prebiotics in the last month
- Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Modified Qing-Ying Decoction
Herbal granules, twice per day for 12 weeks
|
Herbal granules
|
Placebo Comparator: Identical looking placebo
Placebo granules, twice per day for 12 weeks
|
Placebo granules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eczema Area and Severity Index (EASI)
Time Frame: 16 weeks
|
Min value: 0, max value: 72, higher scores mean worse outcome.
To assess the severity of atopic dermatitis
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Oriented Eczema Measure (POEM)
Time Frame: 16 weeks
|
Min value: 0, max value: 28, higher scores mean worse outcome.
To assess the subjective symptoms of subjects.
|
16 weeks
|
Children's Dermatology Life Quality Index (CDLQI)
Time Frame: 16 weeks
|
Min value: 0, max value: 30, higher scores mean worse outcome.
To assess the quality of life of subjects.
|
16 weeks
|
Constitution of Chinese Medicine Questionnaire (CCMQ)
Time Frame: 16 weeks
|
Not a scale.
Based on the answers, a logarithm will be used to determine the type of Chinese Medicine Constitution of the subjects.
To assess the Chinese medicine body constitution of subjects.
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhi-xiu Lin, PhD, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingAtopic Dermatitis | Atopic Dermatitis EczemaNetherlands
-
AbbVieActive, not recruiting
Clinical Trials on Modified Qing-Ying Decoction
-
Jun LiNot yet recruitingMyocardial Infarction | Heart Failure
-
ShuGuang HospitalCompletedGastric Cancer (Diagnosis)
-
Chongqing Traditional Chinese Medicine HospitalNot yet recruiting
-
Xiyuan Hospital of China Academy of Chinese Medical...RecruitingDiarrhea-predominant Irritable Boewl SyndromeChina
-
Xiyuan Hospital of China Academy of Chinese Medical...Recruiting
-
The First Affiliated Hospital of Zhejiang Chinese...Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine; Pujiang... and other collaboratorsRecruiting
-
Chinese University of Hong KongRecruitingAtopic DermatitisHong Kong
-
Beijing University of Chinese MedicineRecruitingModified Zhiwang Decoction Combined With Methotrexate in the Treatment of Early Rheumatoid ArthritisArthritis, RheumatoidChina